Inhibrx Biosciences Inc. (INBX)

Inhibrx Biosciences’ preliminary results for the second fiscal quarter of 2026 showed a wider loss than consensus expected, with EPS of -$2.34 trailing the -$2.28 estimate by -$0.06 when it reported on August 13, 2026. Net income was a loss of roughly $36.6 million, down 27.9% from a loss of about $28.7 million a year ago, alongside an operating loss of around $32.1 million as the company continued funding development work across its pipeline programs, including INBRX-109 and INBRX-106. On a per-share basis, EPS was down 26.5% year over year from -$1.85. Cash usage also remained elevated, with negative operating cash flow of about $29.9 million in the quarter. For the next period, consensus calls for EPS of -$2.39 on revenue of $1.9 million.